Glycorex Transplantation AB (publ) announced that the transfusion unit at the University Hospital of Regensburg today presents its first experience with the UBP-product as a poster at the Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunohämatologie (DGTI). The results are excellent even when exposing the UBP-product to stress, this by exposing it to larger plasma volumes and higher flow rates than what is recommended for the product. The results show that the UBP-product effectively lowers the level of blood group antibodies (anti-A/B antibodies) to low levels. Important blood components such as total protein, albumin, glucose, immunoglobulins, and various antibodies specific to common pathogenic viruses were not significantly affected. The fact that the product has no significant effect on the total amount of antibodies in plasma nor affecting virus-specific antibodies is seen as potentially important for the manufacturing of covid-19 convalescent plasma and for preparation of immunoglobulins (IVIG) with reduced levels of anti-A/B antibodies.